Sammanfattning
In seizure-free patients with epilepsy, the question of whether, and if so when, it is acceptable to discontinue treatment may be difficult to answer. A thorough risk-benefit assessment should be undertaken with the patient and next of kin, during which the consequences of a relapse must be weighed against the disadvantages of continued use of the drug. As a general rule, adult patients should have been seizure-free for at least two years before discontinuation is considered. In children with epilepsy where the prognosis is known to be good, discontinuation may be considered earlier.